Background Alendronate (ALE) is a conventional drug used to treat osteoporosis. Low-magnitude whole-body vibration (WBV) exercise has been developed as a potential treatment for osteoporosis. The aim of this study was to investigate whether low-magnitude WBV could enhance the protective effect of ALE on bone properties in ovariectomized rats. Methods A total of 128 Sprague-Dawley rats were randomly divided into five groups (SHAM, OVX+VEH, OVX+WBV, OVX + ALE, OVX+WBV+ALE). The level of WBV applied was 0.3 g at 45–55 Hz for 20 min/day, 5 day/week and for 3 months. ALE was administered in dose of 1 mg/Kg once a week. Every four weeks eight rats from each group were sacrificed and their blood and both tibiae were harvested. The expression of osteocalcin and CTX in serum was measured by enzyme-linked immunosorbent assay (ELISA) and the tibiae were subjected to metaphyseal three-point bending and μCT analysis. Results Osteocalcin rose after ovariectomy and was not appreciably changed by either alendronate or WBV alone or in combination. Alendronate treatment significantly prevented an increase in CTX. WBV alone treatment did not alter this effect. Compared with the OVX+WBV group, nearly all tested indices such as the BV/TV, TV apparent, Tb.N, Tb.Th, and Conn.D were higher in the OVX+ALE group at week 12.Compared with the OVX+WBV group, certain tested indices such as BV/TV, TV apparent, Tb.N, and Con.D, were higher in the OVX+WBV+ALE group at week 12. At week 12, tibiae treated with WBV+ALE exhibited a significantly higher Fmax compared to the OVX+VEH group, and a significant difference was also found in energy absorption between the OVX+WBV+ALE and OVX+VEH groups. Conclusions Compared with the WBV, ALE was more effective at preventing bone loss and improved the trabecular architecture. However, WBV enhanced the effect of alendronate in ovariectomized rats by inducing further improvements in trabecular architecture.
References
[1]
Kannus P, Parkkari J, Niemi S (1995) Age-adjusted incidence of hip fracture. Lancet 346: 50–51. doi: 10.1016/s0140-6736(95)92679-8
[2]
Miyakoshi N, Itoi E, Kobayashi M, Kodama H (2003) Impact of postural deformities and spinal mobibility on quality of life in postmenopausal osteoporosis. Osteoporos Int 14: 1007–1012. doi: 10.1007/s00198-003-1510-4
[3]
Iwamoto J, Takeda T, Ichimura S, Uzawa M (2003) Comarative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly females with symptomatic vertebral fracture. Keio J Med 52: 230–235. doi: 10.2302/kjm.52.230
[4]
Raisz LG, Smith JA (1989) Pathogenesis, prevention, and treatment of osteoporosis. Annu Rev Med 40: 251–267. doi: 10.1146/annurev.me.40.020189.001343
[5]
Cummings SR. Kelsey JL, Nevitt MC. O'Dowd KJ (1985) Epidemiology of osteoporosis and osteoporotic fracturs. Epidemiol Rev 7: 178–208.
[6]
Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359: 1761–1767. doi: 10.1016/s0140-6736(02)08657-9
[7]
Woolf AD, Akesson K, Hazes JMW (2002) The bone and joint decade monitor project: The burden of musculoskeletal conditions at the start of the new millennium. Osteoporosis Int 13: S84–S85.
[8]
Schenk R, Eqqli P, Fleisch H, Rosini S (1986) Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38: 342–349. doi: 10.1007/bf02555748
[9]
Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet O (1986) Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1: 27–39. doi: 10.1016/8756-3282(85)90012-2
[10]
Schenk R, Merz WA, Muhlbaucr R, Russell RGG, Fleisch H (1973) Effect of ethane-1-hydroxy-1,l-diphosphonate (EHDP) and dichloromethylene diphosphonate (CI2MDP) on the calcification and resorption of cartilage and bone in the tibia1 epiphysis and metaphysis of rats. Calcif Tissue Res 11: 196–214. doi: 10.1007/bf02547219
[11]
Marie PJ, Hott M, Garba MT (1985) Inhibition of bone matrix apposition by (3-amino-l-hydroxypropylidene)-l, l-bisphosphonate (AHPrBP) in mouse. Bone 6: 193–200. doi: 10.1016/8756-3282(85)90053-5
[12]
Thompson DD, Seedor JG, Weinreb M, Rosini S, Rodan GA (1990) Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats. J Bone Miner Res 5: 279–286. doi: 10.1002/jbmr.5650050312
[13]
Ward K, Alsop C, Caulton J, Rubin C, Adams J, et al. (2004) Low magnitude mechanical loading is osteogenic in children with disabling conditions. J Bone Miner Res 19: 360–369. doi: 10.1359/jbmr.040129
[14]
Rubin C, Judex S, Qin YX (2006) Low-level mechanical signals and their potential as a non-pharmacological intervention for osteoporosis. Age Ageing 35: ii32–ii36. doi: 10.1093/ageing/afl082
[15]
Rubin C, Recker R, Cullen D, Ryaby J, McCabe J, et al. (2004) Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: A clinical trial assessing compliance, efficacy, and safety. J Bone Miner Res 19: 343–351. doi: 10.1359/jbmr.0301251
[16]
Gilsanz V, Wren TA, Sanchez M, Dorey F, Judex S, et al. (2006) Low-level, high-frequency mechanical signals enhance musculoskeletal development of young females with low BMD.J Bone Miner Res. 21: 1464–1474. doi: 10.1359/jbmr.060612
[17]
Roelants M, Verschueren SM, Delecluse C, Levin O, Stijnen V (2006) Whole-body-vibration-induced increase in leg muscle activity during different squat exercises. J Strength Cond Res 20: 124–129. doi: 10.1519/r-16674.1
[18]
Marin PJ, Rhea MR (2010) Effects of vibration training on muscle strength: A meta-analysis. J Strength Cond Res 24: 548–556. doi: 10.1519/jsc.0b013e3181c09d22
[19]
Leung KS, Shi HF, Cheung WH, Qin L, Ng WK, et al. (2009) Low-magnitude high-frequency vibration accelerates callus formation, mineralization, and fracture healing in rats. J Orthop Res 27: 458–465. doi: 10.1002/jor.20753
[20]
Shi HF, Cheung WH, Qin L, Leung AH, Leung KS (2010) Low-magnitude high-frequency vibration treatment augments fracture healing in ovariectomy-induced osteoporotic bone. Bone 46: 1299–1305. doi: 10.1016/j.bone.2009.11.028
[21]
Boyd SK, Davison P, Müller R, Gasser JA (2006) Monitoring individual morphological changes over time in ovariectomized rats by in vivo micro-computed tomography. Bone 39: 854–62. doi: 10.1016/j.bone.2006.04.017
[22]
Barbier A, Martel C, Vernejoul MC, Tirode F, Nys M, et al. (1990) The visualization and evaluation of bone architecture in the rat using three-dimensional X-ray microcomputed tomography. J Bone Miner Metab 17: 37–44. doi: 10.1007/s007740050061
[23]
Bauss F, Lalla S, Endele R, Hothorn LA (2002) Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 2002 29: 2200–2208.
[24]
Kharode YP, Sharp MC, Bodine PV (2008) Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery. Methods Mol Biol 455: 111–124. doi: 10.1007/978-1-59745-104-8_8
[25]
Stuermer EK, Sehmisch S, Rack T, Wenda E, Seidlova-Wuttke D, et al. (2010) Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in rat. Langenbecks Arch Surg 395: 163–172. doi: 10.1007/s00423-008-0436-x
[26]
Stuermer EK, Seidlová-Wuttke D, Sehmisch S, Rack T, Wille J, et al. (2006) Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res 21: 89–96. doi: 10.1359/jbmr.050913
[27]
Masud T, Giannini S (2003) Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability. Aging Clin Exp Res 15: 89–98. doi: 10.1007/bf03324485
[28]
Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, et al. (1990) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japannese patients with osteoporosis. Osteoporos Int 10: 183–192. doi: 10.1007/s001980050214
[29]
Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, et al. (2002) The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis:a ramdomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res 63: 606–620. doi: 10.1016/s0011-393x(02)80065-0
[30]
Fleisch H (1987) Bisphosphonates - history and experimental basis. Bone 8: 523–528.
[31]
Schenk R, Eggli P, Fleisch H, Rosini S (1986) Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38: 342–239. doi: 10.1007/bf02555748
[32]
Storm T, Thamsborg G, Steiniche T, Rosini S (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322: 1265–1271. doi: 10.1056/nejm199005033221803
[33]
Watts NB. Harris ST, Genant HK, Wasnich RD, Miller PD, et al. (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323: 73–79. doi: 10.1056/nejm199007123230201
[34]
Reginster JY, Deroisy R, Denis D, Collette J, Lecart MP, et al. (1989) Prevention of post-menopausal bone loss by tiludronate. Lancet 2: 1469–1471. doi: 10.1016/0020-7292(90)90123-3
[35]
Smith ML. Fogelman I. Hart DM, Scott E, Bevan J, et al. (1989) Effect of etidronate disodium on bone turnover following surgical menopause. Calcif Tissue Int 44: 74–79. doi: 10.1007/bf02556464
[36]
Akesson K, Ljunghall S, Jonsson B, Sernbo I, Johnell O, et al. (1995) Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of females. J Bone Miner Res 10: 1823–1829. doi: 10.1002/jbmr.5650101127
[37]
Valimaki MJ, Farrerons-Minguella J, Halse J, Kroger H, Maroni M, et al. (2007) Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther 29: 1937–1949. doi: 10.1016/j.clinthera.2007.09.017
[38]
Calvo MS, Eyre DR, Gundberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17: 333–368. doi: 10.1210/edrv-17-4-333
[39]
Rosen HN, Moses AC, Garber J, lloputaife ID, Ross DS, et al. (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66: 100–103. doi: 10.1007/pl00005830
[40]
Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, et al. (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25: 1468–1486. doi: 10.1002/jbmr.141
[41]
Verschueren SM, Roelants M, Delecluse C, Swinnen S, Vanderschueren D, et al. (2004) Effect of 6-month whole body vibration training on hip density,muscle strength,and postural control in postmenopausal females:a randomized controlled pilot study. J Bone Miner Res 19(3): 352–359. doi: 10.1359/jbmr.0301245
[42]
Oxlund BS, Ortoft G, Andreassen TT, Oxlund H (2003) Low-intensity, high-frequency vibration appear to prevent the decrease in strength of the femur and tibia associated with ovariectomy of adult rats. Bone 32: 69–77. doi: 10.1016/s8756-3282(02)00916-x
[43]
Rubin CT, Lanyon LE (1985) Regulation of bone mass by mechanical strain magnitude. Calcif Tissue Int 37: 411–417. doi: 10.1007/bf02553711
[44]
Frost HM (1982) Mechanical determinants of bone modeling. Metab Bone Dis Relat Res 4: 217–229. doi: 10.1016/0221-8747(82)90031-5
[45]
Lanyon LE (1984) Functional strain as a determinant for bone remodeling. Calcif Tissue Int 36: S56–61. doi: 10.1007/bf02406134
[46]
Goodship AE, Lanyon LE, McFie H (1979) Functional adaptation of bone to increased stress. An experimental study. J Bone Joint Surg Am 61: 539–546.
[47]
Hsieh YF, Robling AG, Ambrosius WT, Burr DB, Turner CH (2001) Mechanical loading of diaphyseal bone in vivo: the strain threshold for an osteogenic response varies with location. J Bone Miner Res 16: 2291–2297. doi: 10.1359/jbmr.2001.16.12.2291
[48]
Wenger KH, Freeman JD, Fulzele S, Immel DM, Powell BD, et al. (2010) Effect of whole-body vibration on bone properties in aging mice. Bone 47: 746–755. doi: 10.1016/j.bone.2010.07.014
[49]
Christiansen BA, Silva MJ (2006) The effect of varying magnitudes of whole-body vibration on several skeletal sites in mice. Ann Biomed Eng 34: 1149–1156. doi: 10.1007/s10439-006-9133-5
[50]
Cardinale M, Wakeling J (2005) Whole body vibration exercises: are vibrations good for you? Br J Sports Med 39: 585–589. doi: 10.1136/bjsm.2005.016857
[51]
Santos-Filho SD, Meyer PF, Ronzio OA, Bonelli L, Fonseca AS, et al. (2010) Whole body vibration exercise: what do you know about scientific interest? Fiep Bull 80: 875–878.
[52]
Bovenzi M (2005) Health effects of mechanical vibration. G Ital Med Lav Ergon 27: 58–64.
[53]
Nelson CM, Brereton PF (2005) The European vibration directive. Ind Health 43: 472–479. doi: 10.2486/indhealth.43.472
[54]
Abercromby AF, Amonette WE, Layne CS, McFarlin BK, Hinman MR, et al. (2007) Vibration exposure and biodynamic responses during whole-body vibration training. Med Sci Sports Exerc 39: 1794–1800. doi: 10.1249/mss.0b013e3181238a0f
[55]
Rubin C, Xu G, Judex S (2001) The anabolic activity of bone tissue, suppressed by disuse, is normalized by brief exposure to extremely low-magnitude mechanical stimuli. FASEB J. 15: 2225–2229. doi: 10.1096/fj.01-0166com
[56]
Garman R, Gaudette G, Donahue LR, Rubin C, Judex S (2007) Low-level accelerations applied in the absence of weight bearing can enhance trabecular bone formation. J Orthop Res 25 (6): 732–740. doi: 10.1002/jor.20354
[57]
Xie L, Rubin C, Judex S (2008) Enhancement of the adolescent murine musculoskeletal system using low-level mechanical vibrations. J Appl Physiol 104: 1056–1062. doi: 10.1152/japplphysiol.00764.2007
[58]
Xie L, Jacobson JM, Choi ES, Busa B, Donahue LR (2006) et al (2006) Low-level mechanical vibrations can influence bone resorption and bone formation in the growing skeleton. Bone 39: 1059–1066. doi: 10.1016/j.bone.2006.05.012
